Meeting
2014 ASCO Annual Meeting
Preclinical evaluation of PARP inhibitors in combination with DNA-damaging agents in a Ewing sarcoma orthotopic xenograft model.
Authors
Elizabeth Stewart
St. Jude Children's Research Hospital, Memphis, TN
Elizabeth Stewart , David Ross Goshorn , Michael A. Dyer , Anang Shelat , Cori Bradley , Alberto S. Pappo , Amos Loh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 10073)
DOI
10.1200/jco.2014.32.15_suppl.10073
Abstract #
10073
Poster Bd #
374
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A biomarker-guided approach to combining PARP inhibitors with radiotherapy in pediatric solid tumors.
First Author: Anang Shelat
Poster
2022 ASCO Annual Meeting
Phase 2 study to evaluate palbociclib in combination with irinotecan and temozolomide in pediatric patients with recurrent or refractory Ewing sarcoma.
First Author: Theodore Willis Laetsch
Poster
2023 ASCO Annual Meeting
Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma.
First Author: Jaydira Del Rivero
Poster
2021 Genitourinary Cancers Symposium
Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer (mCRPC).
First Author: Fadi Taza